This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Oct;59(10):1523.

doi: 10.1001/archneur.59.10.1523.

Mitochondrial therapy for Parkinson disease

Roger N Rosenberg

PMID: 12374488
DOI: 10.1001/archneur.59.10.1523

Editorial

Mitochondrial therapy for Parkinson disease

Roger N Rosenberg. Arch Neurol. 2002 Oct.

. 2002 Oct;59(10):1523.

doi: 10.1001/archneur.59.10.1523.

Author

Roger N Rosenberg

PMID: 12374488
DOI: 10.1001/archneur.59.10.1523

No abstract available

PubMed Disclaimer

Comment on

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Shults CW, et al. Arch Neurol. 2002 Oct;59(10):1541-50. doi: 10.1001/archneur.59.10.1541. Arch Neurol. 2002. PMID: 12374491 Clinical Trial.

Similar articles

Coenzyme Q10.
Pepping J. Pepping J. Am J Health Syst Pharm. 1999 Mar 15;56(6):519-21. doi: 10.1093/ajhp/56.6.519. Am J Health Syst Pharm. 1999. PMID: 10192685 Review. No abstract available.
Clinical trials of coenzyme Q10 in neurological disorders.
Shults CW, Haas R. Shults CW, et al. Biofactors. 2005;25(1-4):117-26. doi: 10.1002/biof.5520250113. Biofactors. 2005. PMID: 16873936 Review. No abstract available.
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Shults CW, et al. Arch Neurol. 2002 Oct;59(10):1541-50. doi: 10.1001/archneur.59.10.1541. Arch Neurol. 2002. PMID: 12374491 Clinical Trial.
Beware the thin, deaf 'type 2' diabetic: maternally inherited diabetes and deafness with systemic (mitochondrial) manifestations.
Jones DL, Greenaway TM. Jones DL, et al. Intern Med J. 2004 Aug;34(8):517-8. doi: 10.1111/j.1444-0903.2004.00659.x. Intern Med J. 2004. PMID: 15317555 No abstract available.
Coenzyme Q10.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2006 Feb 27;48(1229):19-20. Med Lett Drugs Ther. 2006. PMID: 16498307 Review. No abstract available.

See all similar articles

Cited by

Inflammation as a causative factor in the aetiology of Parkinson's disease.
Whitton PS. Whitton PS. Br J Pharmacol. 2007 Apr;150(8):963-76. doi: 10.1038/sj.bjp.0707167. Epub 2007 Mar 5. Br J Pharmacol. 2007. PMID: 17339843 Free PMC article. Review.
Overexpression of Annexin A1 Suppresses Pro-Inflammatory Factors in PC12 Cells Induced by 1-Methyl-4-Phenylpyridinium.
Kiani-Esfahani A, Kazemi Sheykhshabani S, Peymani M, Hashemi MS, Ghaedi K, Nasr-Esfahani MH. Kiani-Esfahani A, et al. Cell J. 2016 Jul-Sep;18(2):197-204. doi: 10.22074/cellj.2016.4314. Epub 2016 May 30. Cell J. 2016. PMID: 27540524 Free PMC article.
Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease.
More SV, Kumar H, Kim IS, Song SY, Choi DK. More SV, et al. Mediators Inflamm. 2013;2013:952375. doi: 10.1155/2013/952375. Epub 2013 Jun 27. Mediators Inflamm. 2013. PMID: 23935251 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information